PSIL-002

PSIL-002 is a non-hallucinogenic serotonin 5-HT₁ receptor modulator which is under development for the treatment of depressive disorders, mood disorders, neurodegenerative disorders, and substance-related disorders.^{[1][2][3][4][5]} Its route of administration is unspecified.^[1] The drug's effects in animals have been described.^[4] PSIL-002 is being developed by Psilera.^[1][2] As of August 2022, it is in the preclinical research stage of development for all indications.^[1][2] The drug is an analogue of dimethyltryptamine (DMT), but its exact chemical structure does not yet seem to have been disclosed.^[3][1]

PSIL-002

Clinical data
Other names	PSIL002
Routes of administration	Unspecified[1]
Drug class	Non-hallucinogenic serotonin 5-HT1 receptor modulator

See also

• PSIL-001
• List of investigational hallucinogens and entactogens
• List of investigational antidepressants